<div class="container">

<table style="width: 100%;"><tr>
<td>method.A</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>
Comparative BA-calculation for Average Bioequivalence with Expanding Limits by the EMA's 'Method A'
</h2>

<h3>Description</h3>

<p>This function performs the required calculations for the mixed (or aggregate)
<abbr><span class="acronym">BE</span></abbr> decision via Average Bioequivalence with Expanding Limits
(<abbr><span class="acronym">ABEL</span></abbr>) based on <abbr><span class="acronym">ANOVA</span></abbr> (‘Method A’) as recommended in <em>Annex I</em>.
</p>


<h3>Usage</h3>

<pre><code class="language-R">method.A(alpha = 0.05, path.in, path.out = tempdir(), file, set = "",
         ext, na = ".", sep = ",", dec = ".", logtrans = TRUE,
         regulator = "EMA", ola = FALSE, print = TRUE, details = FALSE,
         adjust = FALSE, verbose = FALSE, ask = FALSE,
         plot.bxp = FALSE, fence = 2, data = NULL)
</code></pre>


<h3>Arguments</h3>

<table>
<tr style="vertical-align: top;">
<td><code>alpha</code></td>
<td>

<p>Type I Error (<abbr><span class="acronym">TIE</span></abbr>) probability (nominal level of the test).
Conventionally set to 0.05, resulting in a
100(1 – 2<em>α</em>)
confidence interval.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>path.in</code></td>
<td>

<p>Path to the data file for import.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>path.out</code></td>
<td>

<p>Path to save the result file if <code>print=TRUE</code>. You must have
write-permission to the folder. For simplicity your home folder <code style="white-space: pre;">⁠"~/"⁠</code> can be used.<br>
If missing, R’s standard temporary folder will be used.<br>
If a box plot of outliers should be saved (<code>plot.bxp = TRUE</code>), this path will be
used as well.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>file</code></td>
<td>

<p>Name of the dataset for import (<em>without</em> extension). Must be
a string (<em>i.e.</em>, enclosed in single or double quotation marks).
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>set</code></td>
<td>

<p>Name of the sheet of an Excel-file (mandatory). Must be a string
(<em>i.e.</em>, enclosed in single or double quotation marks).
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>ext</code></td>
<td>

<p>File-extension enclosed in single or double quotation marks.
Acceptable are <code style="white-space: pre;">⁠"csv"⁠</code> for character delimited
variables (<abbr><span class="acronym">CSV</span></abbr>) or <code style="white-space: pre;">⁠"xls"⁠</code>, <code style="white-space: pre;">⁠"xlsx"⁠</code> for Excel-files.<br>
The file-extension is not case-sensitive.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>na</code></td>
<td>

<p>Character string denoting missing values. Acceptable are <code style="white-space: pre;">⁠"NA"⁠</code>
(not available), <code style="white-space: pre;">⁠"ND"⁠</code> (not determined), <code style="white-space: pre;">⁠"."⁠</code> (<abbr><span class="acronym">SAS</span></abbr>),
<code style="white-space: pre;">⁠"Missing"⁠</code> (Phoenix WinNonlin), and <code style="white-space: pre;">⁠""⁠</code> (<abbr><span class="acronym">Excel</span></abbr>;
empty cell). Missings will be converted to <code style="white-space: pre;">⁠NA⁠</code> in the imported
data. Defaults to <code style="white-space: pre;">⁠"."⁠</code>.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>sep</code></td>
<td>

<p>Variable separator in the <abbr><span class="acronym">CSV</span></abbr>-file. Acceptable are <code style="white-space: pre;">⁠","⁠</code>
(comma = <code style="white-space: pre;">⁠ASCII 44⁠</code>), <code style="white-space: pre;">⁠";"⁠</code> (semicolon = <code style="white-space: pre;">⁠ASCII 59⁠</code>),
and <code style="white-space: pre;">⁠"\t"⁠</code> (tabulator = <code style="white-space: pre;">⁠ASCII 9⁠</code>). Defaults to <code style="white-space: pre;">⁠","⁠</code>.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>dec</code></td>
<td>

<p>Decimal separator in the <abbr><span class="acronym">CSV</span></abbr>-file. Acceptable are <code style="white-space: pre;">⁠"."⁠</code>
(period = <code style="white-space: pre;">⁠ASCII 46⁠</code>) or <code style="white-space: pre;">⁠","⁠</code> (comma = <code style="white-space: pre;">⁠ASCII 44⁠</code>).
Defaults to <code style="white-space: pre;">⁠"."⁠</code>.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>logtrans</code></td>
<td>

<p>If <code>TRUE</code> (default) the raw data (provided in column <code style="white-space: pre;">⁠PK⁠</code>)
will be internally log-transformed and used in the calculations.
If <code>FALSE</code> the already log-transformed data (provided in the
column <code style="white-space: pre;">⁠logPK⁠</code>) will be used in the calculations.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>regulator</code></td>
<td>

<p>Set regulatory conditions. If <code>"EMA"</code> (default) conventional ABEL will
be used. If <code>"GCC"</code> direct widening to 75.00–133.33% will be used if
<code>CVwR &gt; 30%</code>.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>ola</code></td>
<td>

<p>Defaults to <code>FALSE</code>. If <code>TRUE</code> an outlier analysis based
on the studentized and standardized (aka internally studentized) residuals
of the model estimating <code>CVwR</code> is performed.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>print</code></td>
<td>

<p>If <code>TRUE</code> (default), the function prints its results to a
file. If <code>FALSE</code>, returns a data frame of results.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>details</code></td>
<td>

<p>Defaults to <code>FALSE</code>. If <code>TRUE</code>, the function sends its
results in full precision to a data frame.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>adjust</code></td>
<td>

<p>Defaults to <code>FALSE</code>.<br>
If <code>TRUE</code>, the empiric Type I Error (<em>TIE</em>) is evaluated via simulations
(by the function scABEL.ad of library <code style="white-space: pre;">⁠PowerTOST⁠</code>). Currently
implemented designs are <code style="white-space: pre;">⁠2x2x4⁠</code>, <code style="white-space: pre;">⁠2x2x3⁠</code>, and
<code style="white-space: pre;">⁠2x3x3⁠</code>. If the <em>TIE</em> exceeds the nominal level of
the test <code>alpha</code>, <em>α</em>
is iteratively adjusted until
<em>TIE</em> = <em>α</em> ± 10<sup>–6</sup>.<br>
If <code>ola = TRUE</code> and outlier(s) found – which lead to an always lower –
recalculated <code>CVwR</code>, the assessment is repeated for its value.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>verbose</code></td>
<td>

<p>Defaults to <code>FALSE</code>. If <code>TRUE</code> the ANOVA-table is send to
the console. If <code>ola = TRUE</code> additional information about outliers
are shown.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>ask</code></td>
<td>

<p>Defaults to <code>FALSE</code>. If <code>TRUE</code> the user will be asked whether
an already existing result file (and if outliers are found, the box plot)
should be overwritten.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>plot.bxp</code></td>
<td>

<p>Only observed if <code>ola = TRUE</code> and at least one outlier is found.
If <code>FALSE</code> (default) the box plot will be shown in the graphics
device. If <code>TRUE</code> the box plot will be saved in <abbr><span class="acronym">PNG</span></abbr> format
to <code>path.out</code>.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>fence</code></td>
<td>

<p>Only observed if <code>ola = TRUE</code>. The limit for outlier detection as
a multiplier of the interquartile range. Defaults to 2. Less outliers
will be detected with higher values (not recommended).
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>data</code></td>
<td>

<p>Specification of one of the internal reference datasets (<code style="white-space: pre;">⁠rds01⁠</code> to  <code style="white-space: pre;">⁠rds30⁠</code>).
If given, the arguments <code style="white-space: pre;">⁠path.in⁠</code>, <code style="white-space: pre;">⁠file⁠</code>, <code style="white-space: pre;">⁠set⁠</code>, and <code style="white-space: pre;">⁠ext⁠</code> are
ignored. For its use see the examples.<br>
If not given, defaults to <code>NULL</code> (<em>i.e.</em>, import data
from a file).
</p>
</td>
</tr>
</table>
<h3>Details</h3>

<p>The model for the estimation of <code>CVwR</code> is<br><code>lm(log(PK) ~ sequence + subject%in%sequence + period, data = data[data$treatment == "R", ])</code><br>
where all effects are fixed.<br>
The model for the treatment comparison is<br><code>lm(log(PK) ~ sequence + subject%in%sequence + period + treatment, data = data)</code><br>
where all effects are fixed.<br><br>
Tested designs
</p>

<ul>
<li>
<p> 4-period 2-sequence full replicates<br><code style="white-space: pre;">⁠TRTR | RTRT⁠</code><br><code style="white-space: pre;">⁠TRRT | RTTR⁠</code><br><code style="white-space: pre;">⁠TTRR | RRTT⁠</code>
</p>
</li>
<li>
<p> 2-period 4-sequence replicate<br><code style="white-space: pre;">⁠TR | RT | TT | RR ⁠</code> (Balaam’s design)
</p>
</li>
<li>
<p> 4-period 4-sequence full replicates<br><code style="white-space: pre;">⁠TRTR | RTRT | TRRT | RTTR⁠</code><br><code style="white-space: pre;">⁠TRRT | RTTR | TTRR | RRTT⁠</code>
</p>
</li>
<li>
<p> 3-period 2-sequence full replicates<br><code style="white-space: pre;">⁠TRT | RTR⁠</code><br><code style="white-space: pre;">⁠TRR | RTT⁠</code>
</p>
</li>
<li>
<p> 3-period (partial) replicates<br><code style="white-space: pre;">⁠TRR | RTR | RRT⁠</code><br><code style="white-space: pre;">⁠TRR | RTR ⁠</code> (extra-reference design)
</p>
</li>
</ul>
<p>Data structure
</p>

<ul><li>
<p> Columns must have the headers <code>subject</code>, <code>period</code>,
<code>sequence</code>, <code>treatment</code>, <code>PK</code>, and/or <code>logPK</code>.<br>
Any order of columns is acceptable.<br>
Uppercase and mixed case headers will be internally converted to lowercase headers.
</p>

<ul>
<li> <p><code>subject</code> must be integers or (any combination of) alphanumerics<br><code style="white-space: pre;">⁠[A-Z, a-z, -, _, #, 0-9]⁠</code>
</p>
</li>
<li> <p><code>period</code> must be integer numbers.
</p>
</li>
<li> <p><code>sequence</code> must be contained in the tested designs (numbers or
<em>e.g.</em>, <code style="white-space: pre;">⁠ABAB⁠</code> are not acceptable).
</p>
</li>
<li>
<p> The Test treatment must be coded <code>T</code> and the Reference <code>R</code>.
</p>
</li>
</ul>
</li></ul>
<h3>Value</h3>

<p>Prints results to a file if argument <code>print = TRUE</code> (default).<br>
If argument <code>print = FALSE</code>, returns a data frame with the elements:
</p>

<table>
<tr>
<td style="text-align: left;">
    <code>Design</code> </td>
<td style="text-align: left;"> <em>e.g.</em>, TRTR|RTRT</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>Method</code> </td>
<td style="text-align: left;"> A</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>n</code> </td>
<td style="text-align: left;"> total number of subjects</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>nTT</code> </td>
<td style="text-align: left;"> number of subjects with two treatments of <code>T</code> (full replicates only)</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>nRR</code> </td>
<td style="text-align: left;"> number of subjects with two treatments of <code>R</code>
</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>Sub/seq</code> </td>
<td style="text-align: left;"> number of subjects per sequence</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>Miss/seq</code> </td>
<td style="text-align: left;"> if the design is unbalanced, number of missings per sequence</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>Miss/per</code> </td>
<td style="text-align: left;"> if the design is incomplete, number of missings per period</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>alpha</code> </td>
<td style="text-align: left;"> nominal level of the test</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>DF</code> </td>
<td style="text-align: left;"> degrees of freedom of the treatment comparison</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>CVwT(%)</code> </td>
<td style="text-align: left;"> intra-subject coefficient of variation of the test treatment (full replicates only)</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>CVwR(%)</code> </td>
<td style="text-align: left;"> intra-subject coefficient of variation of the reference treatment</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>swT</code> </td>
<td style="text-align: left;"> intra-subject standard deviation of the test treatment (full replicates only)</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>swR</code> </td>
<td style="text-align: left;"> intra-subject standard deviation of the reference treatment</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>sw.ratio</code> </td>
<td style="text-align: left;"> ratio of intra-subject deviations of <code>T</code> and <code>R</code> (full replicates only)</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>sw.ratio.CL</code> </td>
<td style="text-align: left;"> upper confidence limit of <code>sw.ratio</code> (full replicates only)
  </td>
</tr>
</table>
<ul>
<li>
<p>If reference-scaling is applicable (<em>i.e.</em>, <code>CVwR(%)</code> &gt;30%):
</p>

<table>
<tr>
<td style="text-align: left;">
      <code>L(%)</code> </td>
<td style="text-align: left;"> lower expanded limit of the acceptance range (AR)</td>
</tr>
<tr>
<td style="text-align: left;">
      <code>U(%)</code> </td>
<td style="text-align: left;"> upper expanded limit of the acceptance range (AR)
    </td>
</tr>
</table>
</li>
<li>
<p>If reference-scaling is not applicable (<em>i.e.</em>, <code>CVwR(%)</code> ≤30%):
</p>

<table>
<tr>
<td style="text-align: left;">
      <code>BE.lo(%)</code> </td>
<td style="text-align: left;"> lower limit of the conventional AR (<code style="white-space: pre;">⁠ 80⁠</code>)</td>
</tr>
<tr>
<td style="text-align: left;">
      <code>BE.hi(%)</code> </td>
<td style="text-align: left;"> upper limit of the conventional AR (<code style="white-space: pre;">⁠125⁠</code>)
    </td>
</tr>
</table>
</li>
</ul>
<table>
<tr>
<td style="text-align: left;">
    <code>CL.lo(%)</code> </td>
<td style="text-align: left;"> lower confidence limit of the treatment comparison</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>CL.hi(%)</code> </td>
<td style="text-align: left;"> upper confidence limit of the treatment comparison</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>PE(%)</code> </td>
<td style="text-align: left;"> point estimate of the treatment comparison (aka <abbr><span class="acronym">GMR</span></abbr>)</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>CI</code> </td>
<td style="text-align: left;"> assessment whether the 100(1 – 2<em>α</em>) <abbr><span class="acronym">CI</span></abbr> lies entirely within the acceptance range (<code style="white-space: pre;">⁠pass|fail⁠</code>)</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>GMR</code> </td>
<td style="text-align: left;"> assessment whether the <abbr><span class="acronym">PE</span></abbr> lies entirely within the <abbr><span class="acronym">GMR</span></abbr>-restriction 80.00--125.00% (<code style="white-space: pre;">⁠pass|fail⁠</code>)</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>BE</code> </td>
<td style="text-align: left;"> mixed (aggregate) assessment whether the study demonstrates bioequivalence (<code style="white-space: pre;">⁠pass|fail⁠</code>)</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>log.half-width</code> </td>
<td style="text-align: left;"> half-width of the confidence interval in log-scale
  </td>
</tr>
</table>
<p>If <code>ola = TRUE</code> and at least one studentized outlier was detected:
</p>

<table>
<tr>
<td style="text-align: left;">
    <code>outlier</code> </td>
<td style="text-align: left;"> outlying subject(s)</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>CVwR.rec(%)</code> </td>
<td style="text-align: left;"> intra-subject coefficient of variation of <code>R</code>; recalculated after exclusion of outlier(s)</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>swR.rec</code> </td>
<td style="text-align: left;"> intra-subject standard deviation of the reference treatment after exclusion of outlier(s)</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>sw.ratio.rec</code> </td>
<td style="text-align: left;"> ratio of intra-subject standard deviations of <code>T</code> and <code>R</code> after exclusion of outlier(s); full replicates only</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>sw.ratio.rec.CL</code> </td>
<td style="text-align: left;"> upper confidence limit of <code>sw.ratio.rec</code> (full replicates only)
  </td>
</tr>
</table>
<ul>
<li>
<p>If reference-scaling is applicable (<em>i.e.</em>, <code>CVwR(%)</code> &gt;30):
</p>

<table>
<tr>
<td style="text-align: left;">
      <code>L.rec(%)</code> </td>
<td style="text-align: left;"> recalculated lower expanded limit of the AR</td>
</tr>
<tr>
<td style="text-align: left;">
      <code>U.rec(%)</code> </td>
<td style="text-align: left;"> recalculated upper expanded limit of the AR
    </td>
</tr>
</table>
</li>
<li>
<p>If reference-scaling is not applicable (<em>i.e.</em>, <code>CVwR(%)</code> ≤30):
</p>

<table>
<tr>
<td style="text-align: left;">
      <code>BE.rec.lo(%)</code> </td>
<td style="text-align: left;"> lower limit of the conventional AR (<code style="white-space: pre;">⁠ 80⁠</code>)</td>
</tr>
<tr>
<td style="text-align: left;">
      <code>BE.rec.hi(%)</code> </td>
<td style="text-align: left;"> upper limit of the conventional AR (<code style="white-space: pre;">⁠125⁠</code>)
    </td>
</tr>
</table>
</li>
</ul>
<table>
<tr>
<td style="text-align: left;">
    <code>CI.rec</code> </td>
<td style="text-align: left;"> assessment whether the 100(1–2α) <abbr><span class="acronym">CI</span></abbr> lies entirely within the new acceptance range (<code style="white-space: pre;">⁠pass|fail⁠</code>)</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>GMR.rec</code> </td>
<td style="text-align: left;"> assessment whether the <abbr><span class="acronym">PE</span></abbr> lies entirely within the <abbr><span class="acronym">GMR</span></abbr>-restriction 80.00--125.00% (<code style="white-space: pre;">⁠pass|fail⁠</code>)</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>BE.rec</code> </td>
<td style="text-align: left;"> mixed (aggregate) assessment whether the study demonstrates bioequivalence (<code style="white-space: pre;">⁠pass|fail⁠</code>)</td>
</tr>
<tr>
<td style="text-align: left;">
  </td>
</tr>
</table>
<h3>Warning</h3>

<p>Files may contain a commentary header. If reading from a <abbr><span class="acronym">CSV</span></abbr>-file,
<em>each</em> line of the commentary header <em>must</em> start with <code style="white-space: pre;">⁠"# "⁠</code>
(hashmark space = <code style="white-space: pre;">⁠ASCII 35 ASCII 32⁠</code>). If reading from an Excel-file
all lines preceding the column headers are treated as a comment.
</p>


<h3>Clarification</h3>

<p>The ‘ASCII line chart’ in the result file gives the confidence
limits with filled black squares and the point estimate as a white rhombus.
If a confidence limit exceeds the maximum possible expansion limit, it is
shown as a triangle. Expanded limits are given as double vertical lines.
Unscaled limits, the <abbr><span class="acronym">GMR</span></abbr> restriction, and 100% are given with
single vertical lines. The ‘resolution’ is approximatelly 0.5% and
therefore, not all symbols might be shown. The <abbr><span class="acronym">CI</span></abbr> and <abbr><span class="acronym">PE</span></abbr> take presedence
over the limits and the expanded limits over unscaled ones.
</p>


<h3>Disclaimer</h3>

<p><em>Program offered for Use without any Guarantees and Absolutely No Warranty. No Liability is accepted for any Loss and Risk to Public Health Resulting from Use of this R-Code.</em>
</p>


<h3>Note</h3>

<p>The <abbr><span class="acronym">EMA</span></abbr>’s model specified as ‘Method B’ in <em>Annex I</em> assumes
equal [<em>sic</em>] intra-subject variances of test and reference (like in
2×2×2
trials) – even if proven false in one of the full replicate designs (were
<em>both</em> <em>CV</em><sub>wT</sub> and
<em>CV</em><sub>wR</sub> can be estimated).
Hence, amongst biostatisticians it is called the ‘crippled model’
because the replicative nature of the study is ignored.<br>
The half-width of the <abbr><span class="acronym">CI</span></abbr> in log-scale allows a comparison of
methods (B <em>vs</em> A) where a higher value <em>might</em> point towards
a more conservative decision. In the provided reference datasets – with
one exception – the conclusion of <abbr><span class="acronym">BE</span></abbr> (based on the mixed
<abbr><span class="acronym">CI</span></abbr> and <abbr><span class="acronym">GMR</span></abbr> criteria) agrees between ‘Method A’
and ‘Method B’. However, for the highly incomplete dataset 14
‘Method A’ was <em>liberal</em> (passing by <abbr><span class="acronym">ANOVA</span></abbr> but
failing by the mixed effects model).<br><br>
Reference-scaling is acceptable for <em>C</em><sub>max</sub> (immediate release products) and <em>C</em><sub>max,ss</sub>,
<em>C</em><sub>τ,ss</sub>, and
<sub>partial</sub><em>AUC</em> (modified release products). However, quoting the <abbr><span class="acronym">BE</span></abbr> guideline:<br><cite>The applicant should justify that the calculated intra-subject
variability is a reliable estimate and that it is not the result of
outliers.</cite><br>
Quoting the Q&amp;A on the Revised EMA Bioequivalence Guideline:<br><cite>... a study could be acceptable if the bioequivalence
requirements are met both including the outlier subject (using the
scaled average bioequivalence approach and the within-subject CV with
this subject) and after exclusion of the outlier (using the within-subject
CV without this subject).<br>
An outlier test is not an expectation of the medicines agencies but
outliers could be shown by a box plot. This would allow the medicines
agencies to compare the data between them.</cite><br><br>
The <abbr><span class="acronym">EMA</span></abbr>’s method of reference-scaling for highly
variable drugs / drug products is currently recommended in other jurisdictions
as well (<em>e.g.</em>, the <abbr><span class="acronym">WHO</span></abbr>; <abbr><span class="acronym">ASEAN</span></abbr> States, Australia, Belarus,
Brazil, Chile, Egypt, the Eurasian Economic Union, the East African Community,
New Zealand, the Russian Federation).<br><br>
In a pilot phase the <abbr><span class="acronym">WHO</span></abbr> accepted reference-scaling for <em>AUC</em> (4-period full replicate
studies are mandatory in order to assess the variability associated with each product).
It was an open issue how this assessment should be done. In Population Bioequivalence (<abbr><span class="acronym">PBE</span></abbr>)
and Individual Bioequivalence (<abbr><span class="acronym">IBE</span></abbr>) the
<em>s</em><sub>wT</sub>/<em>s</em><sub>wR</sub> ratio was assessed and similar
variability was concluded for a ratio within 0.667–1.500. However, the power
of comparing variabilities in a study designed to demonstrate <abbr><span class="acronym">ABE</span></abbr>
is low. This was one of the reasons why <abbr><span class="acronym">PBE</span></abbr> and <abbr><span class="acronym">IBE</span></abbr> were
not implemented in regulatory practice. An alternative approach is given in the
<abbr><span class="acronym">FDA</span></abbr>’s draft ANDA guidance. Variabilities are
considered comparable if the upper confidence limit of
<em>σ</em><sub>wT</sub>/<em>σ</em><sub>wR</sub> is less
than or equal to 2.5.<br>
In 2021 the requirement of comparing variabilities was lifted.
</p>


<h3>Author(s)</h3>

<p>Helmut Schütz, Michael Tomashevskiy, Detlew Labes
</p>


<h3>References</h3>

<p>European Medicines Agency, Committee for Medicinal Products for Human Use. <em>Guideline on the Investigation of Bioequivalence.</em> CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **. London. 20 January 2010. <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf">online</a>
</p>
<p>European Generic and Biosimilar Medicines Association. 3<sup>rd</sup><abbr><span class="acronym">EGA</span></abbr> Symposium on Bioequivalence. <em>Questions and Answers on the Revised <abbr><span class="acronym">EMA</span></abbr> Bioequivalence Guideline.</em> London. 1 June 2010. <a href="https://www.medicinesforeurope.com/wp-content/uploads/2016/03/EGA_BEQ_QA_WEB_QA_1_32.pdf">online</a>
</p>
<p>European Medicines Agency, Committee for Medicinal Products for Human Use. <em>Questions &amp; Answers: positions on specific questions addressed to the Pharmacokinetics Working Party (PKWP).</em> EMA/618604/2008 Rev. 13. London. 19 November 2015. <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-positions-specific-questions-addressed-pharmacokinetics-working-party_en.pdf">online</a>
</p>
<p>European Medicines Agency. <em>Clinical pharmacology and pharmacokinetics: questions and answers. 3.1 Which statistical method for the analysis of a bioequivalence study does the Agency recommend? Annex I</em>. EMA/582648/2016. London. 21 September 2016. <a href="https://www.ema.europa.eu/en/documents/other/31-annex-i-statistical-analysis-methods-compatible-ema-bioequivalence-guideline_en.pdf">online</a>
</p>
<p>Executive Board of the Health Ministers’ Council for GCC States. <em>The GCC Guidelines for Bioequivalence. Version 3.0.</em> May 2021. <a href="https://www.sfda.gov.sa/sites/default/files/2021-10/GCC_Guidelines_Bioequivalence.pdf">online</a>
</p>
<p>Health Canada. <em>Guidance Document. Conduct and Analysis of Comparative Bioavailability Studies.</em> Ottawa. 2018/06/08. <a href="https://www.canada.ca/content/dam/hc-sc/documents/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/bioavailability-bioequivalence/conduct-analysis-comparative.pdf">online</a>
</p>
<p>European Medicines Agency, Committee for Medicinal Products for Human Use. <em>Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms.</em> EMA/CPMP/EWP/280/96 Corr1. London. 20 November 2014. <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmacokinetic-clinical-evaluation-modified-release-dosage-forms_en.pdf">online</a>
</p>
<p>World Health Organization, Prequalification Team: medicines. <em>Guidance Document: Application of reference-scaled criteria for AUC in bioequivalence studies conducted for submission to PQTm.</em> Geneva. 22 November 2018. <a href="https://extranet.who.int/prequal/sites/default/files/documents/AUC_criteria_November2018.pdf">online</a>
</p>
<p>World Health Organization. <em>Application of reference-scaled criteria for AUC in bioequivalence studies conducted for submission to PQT/MED.</em> Geneva. 02 July 2021. <a href="https://extranet.who.int/pqweb/sites/default/files/documents/AUC_criteria_July2021.pdf">online</a>
</p>
<p>U.S. Food and Drug Administration, Center for Drug Evaluation and Research. <em>Draft Guidance for Industry. Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA.</em> August 2021. <a href="https://www.fda.gov/media/87219/Download">download</a>
</p>
<p>Labes D, Schütz H. <em>Inflation of Type I Error in the Evaluation of Scaled Average Bioequivalence, and a Method for its Control.</em> Pharm Res. 2016; 33(11): 2805–14. <a href="https://doi.org/10.1007/s11095-016-2006-1">doi:10.1007/s11095-016-2006-1</a>
</p>


<h3>See Also</h3>


<table>
<tr>
<td style="text-align: left;">
    <code>method.B</code> </td>
<td style="text-align: left;"> evaluation by a linear mixed effects model (subjects random)</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>ABE</code> </td>
<td style="text-align: left;"> evaluation for conventional (unscaled) Average Bioequivalence
  </td>
</tr>
</table>
<h3>Examples</h3>

<pre><code class="language-R"># Importing from a CSV-file, using most of the defaults: variable
# separator colon, decimal separator period, no outlier-analyis,
# print to file.
# Note: You must adapt the path-variables. The example reads from
# the data provided by the library. Write-permissions must be granted
# for 'path.out' in order to save the result file. Here the default
# (R's temporary folder) is used. If you don't know where it is,
# type tempdir() in the console.

path.in  &lt;- paste0(find.package("replicateBE"), "/extdata/")
method.A(path.in = path.in, file = "DS", set = "01", ext = "csv")
# Should result in:
#   CVwT               :  35.16%
#   swT                :   0.34138
#   CVwR               :  46.96% (reference-scaling applicable)
#   swR                :   0.44645
#   Expanded limits    :  71.23% ... 140.40% [100exp(±0.760·swR)]
#   swT / swR          :   0.7647 (similar variabilities of T and R)
#   sw-ratio (upper CL):   0.9324 (comparable variabilities of T and R)
#   Confidence interval: 107.11% ... 124.89%  pass
#   Point estimate     : 115.66%              pass
#   Mixed (CI &amp; PE)    :                      pass
#
# Internal reference dataset 01 used and results to R's
# temporary folder. Additional outlier-analyis.
method.A(ola = TRUE, data = rds01)
# Should give the same as above. Additionally:
#   Outlier fence      :  2×IQR of studentized residuals.
#   Recalculation due to presence of 2 outliers (subj. 45|52)
#   CVwR (outl. excl.) :  32.16% (reference-scaling applicable)
#   swR (recalculated) :   0.31374
#   Expanded limits    :  78.79% ... 126.93% [100exp(±0.760·swR)]
#   swT / swR (recalc.):   1.0881 (similar variabilities of T and R)
#   sw-ratio (upper CL):   1.3282 (comparable variabilities of T and R)
#   Confidence interval: pass
#   Point estimate     : pass
#   Mixed (CI &amp; PE)    : pass
# Same dataset. Show information about outliers and the ANOVA-table.
method.A(ola = TRUE, print = FALSE, verbose = TRUE, data = rds01)
# Generate the data.frame of results (full precision) and show it
# in the console
x &lt;- method.A(ola = TRUE, details = TRUE, print = FALSE, data = rds01)
print(x, row.names = FALSE)
#
# Assess the Type I Error and iteratively adjust alpha if necessary.
# Not run: due to timing policy of CRAN for examples

method.A(adjust = TRUE, data = rds01)
# Should give in the result file:
#   Assessment of the empiric Type I Error (TIE); 1,000,000 studies simulated.
#     TIE not &gt; nominal 0.05; consumer risk is controlled.
#
# Same with recalculation based on outliers, iteratively adjust alpha
# if necessary

method.A(ola = TRUE, adjust = TRUE, data = rds01)
# Should give in the result file:
#   Assessment of the empiric Type I Error (TIE) based on original CVwR;
#   1,000,000 studies simulated.
#     TIE not &gt; nominal 0.05; consumer risk is controlled.
#   Assessment of the empiric Type I Error (TIE) based on recalculated CVwR;
#   1,000,000 studies in each of the 8 iterations simulated.
#     TIE for alpha 0.050000         : 0.07018
#     TIE for adjusted alpha 0.033416: 0.05000
#
# Repeat the evaluation with the adjusted alpha.

method.A(alpha = 0.033416, ola = TRUE, adjust = TRUE, data = rds01)
# Should give in the result file:
#   alpha              :   0.033416 (93.3168% CI)
#   Confidence interval: 106.16% ... 126.00%  pass
#   Point estimate     : 115.66%              pass
#   Mixed (CI &amp; PE)    :                      pass
#   Assessment based on recalculated CVwR 32.16%
#   Confidence interval: pass
#   Point estimate     : pass
#   Mixed (CI &amp; PE)    : pass
#   Assessment of the empiric Type I Error (TIE) based on original CVwR;
#   1,000,000 studies simulated.
#     TIE not &gt; nominal 0.05; consumer risk is controlled.
#   Assessment of empiric Type I Error (TIE) based on recalculated CVwR;
#   1,000,000 studies in each of the 8 iterations simulated.
#     TIE for alpha 0.033416         : 0.05000
#     TIE not &gt; nominal 0.05; consumer risk is controlled.
</code></pre>


</div>